Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status-Reference-Cited by-同舟云学术

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Published:2014-09 Issue:9 Volume:9 Page:1345-1353
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Douillard Jean-Yves,Ostoros Gyula,Cobo Manuel,Ciuleanu Tudor,Cole Rebecca,McWalter Gael,Walker Jill,Dearden Simon,Webster Alan,Milenkova Tsveta,McCormack Rose

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Therapeutic advances in non-small cell lung cancer;Vallières;Thorax,2012

2. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies;Li;J Clin Oncol,2013

3. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

4. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer;Goto;J Thorac Oncol,2012

Cited by 398 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors;Future Oncology;2024-09-04

2. ‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma;Journal of Cancer Research and Clinical Oncology;2024-07-27

3. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial;Nature Medicine;2024-06-19

4. Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing;Expert Review of Anticancer Therapy;2024-04-02

5. The Potential of Cell-Free DNA in Cancer: towards Standardization and Optimization for Enhanced Diagnosis and Monitoring;J BIOL REG HOMEOS AG;2024